A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

Inclusion Criteria:

• Men and women aged 40 or older with idiopathic Parkinson's disease on stabledopaminergic therapy for at least 1 month. The UK Brain Bank Criteria will be used toestablish the diagnosis of Parkinson's disease. Women must be post menopausal or agreeto avoid pregnancy. Modified Hoehn & Yahr staging < 3 and MoCA score must be greaterthan 21 but less than 28. Geriatric Depression Scale (GDS) is a sensitive and specificscreen for depression in the Parkinson's disease population. GDS scores of < 5 will beincluded in the study.

Exclusion Criteria:

• Patients with secondary dementia, severe depression and atypical Parkinson's syndromesor Parkinson's plus will be excluded from the study. Patients on acetylcholineesterase or NMDA inhibitor medication will be excluded from the study. Patients withhistory of brain surgery for Parkinson's disease, stroke or significant head injury,active epilepsy will be excluded. Patients on Amantidine, neuroleptics,metoclopramide, alphamethyldopa within the last 6 months will be excluded. Individualsusing meperidine, and tramadol will be excluded. Patients with congestive heartfailure or myocardial infarction will also be excluded to avoid vascular dementia.